755039-56-6 Usage
Description
(R)-4-(8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxybenzoic acid, also known as 5-Methyltetrahydropteroylglutamic acid, is a complex chemical compound that belongs to the class of pteridines and folic acid derivatives. It is a member of the vitamin B9 family and plays a crucial role in various biological processes, including cell growth, division, and metabolism. Its intricate chemical structure and properties make it an important component in the field of pharmaceuticals and nutritional supplements.
Uses
Used in Pharmaceutical Industry:
(R)-4-(8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxybenzoic acid is used as a therapeutic agent for preventing and treating folate deficiency and its associated conditions. It is particularly effective in managing megaloblastic anemia and neural tube defects, which are often linked to inadequate levels of folate in the body.
Used in Nutritional Supplements:
In the nutritional supplement industry, (R)-4-(8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxybenzoic acid serves as an essential component in various formulations designed to support overall health and well-being. Its role in cell growth, division, and metabolism makes it a valuable addition to supplements aimed at promoting optimal bodily function and maintaining a balanced nutritional profile.
Check Digit Verification of cas no
The CAS Registry Mumber 755039-56-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,5,5,0,3 and 9 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 755039-56:
(8*7)+(7*5)+(6*5)+(5*0)+(4*3)+(3*9)+(2*5)+(1*6)=176
176 % 10 = 6
So 755039-56-6 is a valid CAS Registry Number.
755039-56-6Relevant articles and documents
Compound containing methotrexate structure as well as preparation method and application thereof
-
, (2021/11/14)
The invention discloses a compound of a general formula (I) containing a tetrahydrotrexate structure and a preparation method and application thereof. The invention also discloses a composition containing the methotrexate compound or a pharmaceutically ac
Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold
Remillard, David,Buckley, Dennis L.,Seo, Hyuk-Soo,Ferguson, Fleur M.,Dhe-Paganon, Sirano,Bradner, James E.,Gray, Nathanael S.
, p. 1443 - 1449 (2019/10/11)
Recent reports have highlighted the dual bromodomains of TAF1 (TAF1(1,2)) as synergistic with BET inhibition in cellular cancer models, engendering interest in TAF/BET polypharmacology. Here, we examine structure activity relationships within the BI-2536 PLK1 kinase inhibitor scaffold, previously reported to bind BRD4. We examine binding by this ligand to TAF1(2) and apply structure guided design strategies to discriminate binding to both the PLK1 kinase and BRD4(1) bromodomain while retaining activity on TAF1(2). Through this effort we discover potent dual inhibitors of TAF1(2)/BRD4(1), as well as biased derivatives showing marked TAF1 selectivity. We resolve X-ray crystallographic data sets to examine the mechanisms of the observed TAF1 selectivity and to provide a resource for further development of this scaffold.
REGULATING CHIMERIC ANTIGEN RECEPTORS
-
Page/Page column 323; 324, (2018/09/08)
This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.
